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for a barium swallow and meal. On radiological examina-
lion a very large and atonic oe ophagus wa demonstrated.
There was also a suggestion of muscular inco-ordination
at the initiation of deglutition, which could be the result
of a pseudobulbar palsy. However, a she was known to
have amyloid disease and did not have any other signs of
bulbar palsy, this disease and other conditions uch a
scleroderma and enile degeneration could be reasonably
left out of the differential diagno i . Uniform enlargement
of the small bowel was also found.
DISCUSSIO
Although there have been few radiological studies of the
oesophagus in primary amyloidosis,' these features correlate
well with most findings described. Korelitz and Spindell'
showed abnormal retention of barium in the valleculae
and narrowing of the gullet. Hertzman and others' re-
ported, 'The oesophagus appeared dilated and aperistaltic'.
They also mentioned associated gastro-oesophageal reflux,
which was not seen in this case. Toriola et al." recorded
a patient who required a bypass operation for amyloid
disease of the oesophagus: the barium wallow howed
dilation of the upper two-third of the oe ophagu and a
compl te hold·up in the lower third.
S MMARY
The absence of long-standing chronic illnes, the multi focal
nature and the failure to prove a definite a ociation with a
myelomalOu state suggest tha t this is a ca e of primary
amyloidosis involving (so far as is known) the heart, ga tIO-
intestinal tract (oesophagus and small intestine) ... nd the lymph
node in the groin.
I wish to thank PIOf. J. H. Louw. Head of the Department
of Surgery, and PIOf. J. F. BIOck, of the Department of
Medicine, for making their clinical data available. ] should
also like to thank Or J. G. Burger, Medical Superintendent of
Groote Schuur Ho pital, for permis ion to publish.
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CLINICAL RESPONSE TO LONG·TERM PROPRANOLOL THERAPY IN
HYPERTHYROIDISM*
BERNARD PIMSTO E, M.R.C.P., B. JOFFE, t M.R.C.P., EVILLE PIM TONE, F.C.P. (S.A.), F. BON' ICI, F.C.P. (S.A.)
A 'D W. P. U. JACKSON, F.R.C.P., Thyroid Clinic, Croote Se/wur Hospital, Cape TOlI'n
Propranolol has been shown to be effective in hyper-
thyroidism in a variety of situations. These include thyro-
toxic crises,'" preparation for subtotal thyroidectomy,' the
control of residual thyrotoxic symptoms after radioactive
iodine therapy' and in some cases of thyrotoxic myo-
pathy"
Standard antithyroid drugs are not without serious side-
effects, and their prolonged use in hyperthyroidism may
be complicated by the frequent need to adjust dosage to
the changing clinical status of the patient. They al 0 inter-
fere with "'1 tests of thyroid function during treatment.
Propranolol, by contrast, causes few unpredictable side-
effects if patients are appropriately selected, does not ap-
pear to induce hypothyroidism, and allows thyroid func-
tion to be te ted during therapy.· The present tudy was
therefore undertaken to assess the effectiveness of this
drug given as sole long-term treatment in hyperthyroidism.
PATlE TS AND METHODS
The trial group consisted of 27 patients (23 females and 4
males) attending the Thyroiri Clinic, Groote Schuur Ho -
pital, who were considered suitable candidates for long-
term medical therapy and in whom there were no ob-
vious contraindications to the u e of propranolol, such as
bronchospasm or overt cardiac failure. All were hyper-
thyroid by standard clinical and laboratory criteria. Their
ages ranged from 21 to 63 year.
Propranolol (lnderal, ICI) wa instituted as the sole
therapeutic agent after as essment according to Wayne'
therapy index;" each patient had an initial score of 20 or
more. The starting dose of propranolol was generally 40
mg. orally t.d.s. Patients were reasse sed at monthly (or
'Date received: I August 1969.
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more frequent) intervals, and if clinical response was
judged to be partial but inadequate the dose was in-
creased (to a maximum of 120 mg. q.i.d.). Those who
responded poorly were given eo-Mercazole aft r final cli-
nical assessment for the trial.
After an average period of observation of 5 months
(range I - 8 month), each subject wa again carefully
assessed clinically and a final therapy index score was
assigned. Where possible, repeat radioactive iodine ('''I)
neck uptakes were also performed. On the basis of these
2 criteria, patients were then divided into 4 group : those
with an adequate clinical response (final therapy index
score <5) and normal "'I studies (6- and 24-hour neck
uptakes less than 40 and 50% respectively); those with an
adequate response but elevated "'I uptakes; those with a
partial clinical re pon e (final therapy index between 5
and 10 all the e had elevated "'I uptakes; and those
with a poor clinical response (therapy index score > 10).
RESULTS
Croups of Responders
As indicated in Table I, 47 0 0 of the erie were con-
sidered to have had an adequate clinical re ponse when
finally reassessed. In all cases marked subjective and ob-
jective clinical improvement was seen within the fir t few
weeks after commencement of therapy, and the do e of
propranolol required was comparatively small. Indeed,
just under half of these patient eemed to have become
euthyroid again a indicated b normal repeat "'1 neck
uptakes. They could be differentiated from the patients
who remained with elevated repeat uptakes, however, by
their greater gain in weight.
1204 S.A. EDICAL JOURNAL 27 September 1969
TABLE L CLI ICAL A 'D INVESTIGATI E DATA ON 27 PATIE TS
GIVEN LONG-TERM PROPRA 'OLOL 1 HYPERTHYROIDISM
A furlher 34% of patients showed some degree of clini-
cal improvement but were left with at least one important
thyrotoxic symptom-usually per istent loss of weight.
Features that generally improved in thi group were
nervousness, palpitation, exce s sweating and tremor. The
average propranolol dose ultimately employed here was
double that u ed in the first two groups. Repeat 1311 uptakes
were all elevated.
Finally, a comparatively mall number (19%) responded
poorly to the drug. They persisted with numerous thyro-
toxic features. At least 2 patients in thi group admitted
to taking their medication irregularly.
Initial ""1 studies were similar in all 4 group of re-
ponder .
Side-Ef]ecB'
Three patient developed ide-effects severe enough to
warrant premature cessation of therapy. In one, con-
ge tive cardiac failure supervened ome weeks after pro-
pranolol was tarted; another developed erythema multi-
forme after several months; and the third patient had
evere bronchospasm after 5 months on large doses.
Evanescent attacks of mild bronchospasm occurred in
two other ubject.
EfJect of Propranolol on Specific ThyrOTOxic Features
Myopathy occurred as a prominent clinical feature in
4 patients; 3 of them howed marked clinical improve-
ment while on the drug, with a rapid return of normal
muscle power. Details of these and other cases of myo-
pathy have been previously reported.'
Amenorrhoea was a clinical feature in 7 women, and 4
noticed a return of normal men truation within a month
or two of starting therapy.
Improvement of these features occurred in patients
who, at the end of the trial period, still had ele ated 1311
uptakes, suggesting a true effect of propranolol, and not a
coincident improvement due to spontaneous remission.
Lid lag and retraction, observed in the majority of sub-
jects in the serie , appeared to be completely unaffected
by the drug.
duced by propranolol i not yet clear and is being current-
ly evaluated. Of particular interest were the 7 patients in
this group who till showed elevated 1311 neck uptakes at
the end' for their failure to gain as much weight a the
patients who had become euthyroid suggests a degree of
persisting 'hypermetabolism'. Our preliminary data on the
effect of propranolol on basal metabolisms tends to con-
firm thi.
Initial ""1 neck uptakes were unhelpful in predicting
which patients were likely to respond satisfactorily to
propranolol, but some indication wa provided by the
observation that those who did well could be controlled
from the beginning on the starting dose. Where this had to
be increased during the period of follow-up, eventual
clinical response was usually incomplete.
Significant side-effects occurred in 3 patients; with-
drawal of the drug and substitution of alternate therapy
led to their resolution in each case. Thus there is little
objective confirmation for the assertion that long-conti-
nued use of propranolol is fraught with risk in thyrotoxi-
cosis: provided proper care is taken.
It seems unlikely that all the beneficial effects observed
with propranolol in this study can be attributed solely to
adrenergic-f:l-receptor blockade. While proprano~ol-in­
duced improvement in cardiovascular manifestations,
tremor and anxiety in thyrotoxicosis is generally regarded
as being largely the result of uch sympathetic inhibi-
tion,'-"lO the improvement of myopathy and return of men-
struation noted in some of our patients are not easily
explicable on these grounds. That the response was not
coincident with spontaneous remission, but reflected a true
effect of propranolol, is suggested by the persistence of
elevated mI uptakes in the majority of these patients.
However, the precise mechanism awaits clarification.
With regard to the practical role of propranolol in the
long-term medical management of hyperthyroidism, cer-
tain tentative conclusions can be drawn from this study.
Although obviously inferior to the standard antithyroid
drugs for routine therapy, it could be profitably employed
in relatively low dosage (say 40 mg. q.i.d.) for the first
few weeks of treatment in suitable subjects. Where a good
response-including some increase in weight-is rapidly
observed, it would seem rational to persevere with the
drug. In cases where response, as judged by a standard
therapy index, is in.::omplete, the addition of a thyroid-
blocking agent (e.g. Neo-Mercazole) in low dosage may
prove successful, lessening the risks of induced hypo-
thyroidism and further thyroid enlargement. We are at
present assessing the effects of thi therapeutic approach.
Facilities for regular patient-supervision and follow-up
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Propranolol was capable of adequately controlling 47%
of cases when used as the sole therapeutic agent in the
long-term management of hyperthyroidi m of all grades
of severity. A proportion of those who responded well
eemed to have gone into remission when subsequently re·
tested with '''I, although the over-all percentage that did
o is less than reported after 6 month' of carbimazole
therapy.' Whether the remission was spontaneou or in-
SUMMARY
Twenty-seven patients with hyperthyroidism were treated solely
with propranolol, an adrenergic-f:l-receptor blocking agent, for
an average period of 5 months. They were then reassessed
according to Wayne's therapy index and 47% of the series were
considered to have responded adequately. Just under half of
these had normal radioactive iodine (UlI) neck uptakes when
relested. A further 34% showed some clinical improvement but
were left with at least one major thyrotoxic manifestation-
usually failure to gain weight. The remaining subjects were
poorly ontrolIed on therapy.
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Patients who did well could be controlled from the out et
by relatively small doses of propranolol. Side-effects requir-
ing premature cessation of therapy occurred in 3 cases: these
ubsided when alternative therapy was given. The beneficial
effects on myopathy and menstruation noted in ome patients
suggested that the drug's effectiveness in thyrotoxicosis might
not be entirely due to sympathetic blockade. A practical role
for the use of propranolol in the long-term management of
hyperthyroidism is cautiously defined.
The costs of this study were defrayed by a grant from the
South African Council for Scientific and Industrial Research.
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AMPTELIKE AA KONDIGI G OFFICIAL A OU CEMENT
WYSIGING VAN VERORDENINGE AMENDMENT OF BYLAWS
IN DIE VERBYGAAN : PASSING EVENTS
Dr 1. F. Alldersoll, of the University of Pretoria and H. F.
Verwoerd Hospital. is overseas at present and will attend the
1st World Symposium on Twins in Rome and the 3rd Inter-
national Congress on Congenital Malformations at The Hague.
Dr D. S. C. Procter, surgeon, is practising at 1503 Oasim orth,
Havelock Street. Port Elizabeth. Telephones: rooms 2-2886,
residence 51-2867.
Dr. D. S. C. Procter, chirurg, praktiseer te Oasim-noord 1503,
Havelockstraat, Port Elizabeth. Telefoonnommers: spreek-
kamer 2-2886, woning 51-2867.
Hiermee word vir algemene kennisname aangekondig dat twee
van die Vereniging se verordeninge gedurende die Federale
Raadsvergadering wat op I - 3 J ulie 1969 te Pretoria gehou is,
gewysig is. In hul gewysigde vorm lees die verordeninge soos
volg:
Verordellillg 9(0). Die jaarlikse subskripsie betaalbaar aan die
Vereniging sal 'n bedrag wees wat deur die Raad bepaal sal
word in ooreenstemming met die prosedure wat bepaal i in
Verordening 6I(b) tesame met 'n bedrag wat bepaal sal word
deur die tak in die area waarvan die lid woonagtig is, met
die voorbehoud dat enige lid, waar ookal woonagtig, wat na
31 Januarie van enige jaar aangeneem word, een-twaalfde
van die totale jaarlikse subskripsie vir iedere oorblywende
maand van daardie jaar sal betaal.
Verordening ]](0). As 'n lid se subskripsie vir enige jaar nie
op of voor 30 Junie van daardie jaar betaal is nie, hou hy
ipso facio (maar behoudens wat hierna deur die Reglemente
bepaal word en sonder om sy aanspreeklikheid teenoor die
Vereniging te prejudisieer) van daardie dag af op om lid te
wees; op voorwaarde egter dat hy, by betaling van alle
deur horn verskuldigde subskripsies voor 30 September van
dieselfde jaar, en indien hy verlciesbaar is, sonder herkiesing













Prof. J. H. S. Gear, Director of the South African Institute for
Medical Research and Poliomyeliti Re earch Foundation, has
been appointed Vi iting Professor of Tropical Health at the
University of Harvard, and left on 3 September to take up
this post for a period of 6 months.
In addition to giving several lectures in the UK and SA, he
will attend medical genetic centres, intensive care units,
rheumatology clinics and research workers on lipoprotein dis-
turbances in those countries and in Germany and Japan. He




It is hereby notified for general information that two of the
Association's Bylaws were amended at the meeting of the
Federal Council held in Pretoria on I - 3 July 1969. The By-
laws in their amended form read as follows:
Bylaw 9(a). The annual subscription to the Association shall
b~ such as may be determined by the Council in accordance
with the procedure contained in Bylaw 6I(b) plus such
amount as may be determined by the branch in whose area
a member is resident, provided that any member wherever
resident who is admitted after 31 January in any year, shall
pay one-twelfth of the total annual subscription for each re-
maining month of that year.
Bylaw 11(0). If the subscription of a member for any year
shall not have been paid on or before 30 June in that year,
he shall, ipso facto (but save as otherwise provided in the
Regulations and without prejudice to bis liability to the As-
sociation), cease to be a member from that day, provided
that upon payment before 30 September in the same year of
all subscriptions due from him, he shall, if eligible, be re-
stored to membership without re-election.
By order of the Council
A. H. Tonkin
SecretaryOp las van die Raad
A. H. Tonkin
Sekretaris
**
Posbus 1521
Pretoria
5 September 1969
